ACEMg® is designed to preserve hearing in people who have experienced hearing loss
ANN ARBOR, Mich., June 17, 2025
Soundbites, a Public Benefit Corporation dedicated to hearing preservation for everyone, today announces The United States Patent and Trademark Office (USPTO) has issued patent 12,329,775. The patent covers a nutraceutical, known as ACEMg® in medical literature and sold under the Soundbites® brand as softgel capsules, designed to preserve or restore hearing in people who have already experienced hearing loss unrelated to viral infection.
"I have found ACEMg to be of clear benefit for patients. These real changes are clinically important. The significance of this achievement cannot be overstated," says Dr. Glenn Green, M.D., Kresge Hearing Research Institute at the University of Michigan.
"I have found ACEMg to be of clear benefit for patients. These real changes are clinically important. The significance of this achievement cannot be overstated," says Dr. Glenn Green, M.D., Kresge Hearing Research Institute at the University of Michigan.
According to the allowed
claims, daily dosing over at least three months can improve hearing thresholds
by 15% or more, measurable through distortion-product otoacoustic (OAE)
emissions across frequencies from 1 kHz to 10 kHz. Additional claims extend the
use of the ACEMg formulation to lowering the severity or risk of dementia and
Alzheimer's disease in at-risk individuals with, or likely to develop,
sensorineural hearing loss (SNHL). "The new patent is more
than a legal milestone—it's a big step forward for hearing health," says Barry
Seifer, Founder and CEO. "Soundbites has translated 20 years of auditory
research into a daily supplement, and this patent safeguards our ability to
continue advancing clinically-backed innovation to protect and preserve the
ability to hear." SNHL, or inner ear hearing
loss, is one of the most common and incurable chronic health disabilities
worldwide, impacting about 1.5 billion people. Another 1.4 billion young adults
ages 12-35 are considered at risk, mainly from exposure to loud music at bars,
clubs, festivals, and from personal music players. Common consequences of SNHL
include tinnitus, hyperacusis, and hidden hearing loss, and hearing
preservation is now understood to be the major risk mitigating factor for
dementia. Clinical findings from a two-year, real-world study are the basis for the follow-on, IRB-approved OTIS Study now
underway. This 24-week, Phase IV, open-label, post-marketing real-world
evidence/real-world data (RWE/RWD) study on ACEMg is being conducted by
participants at home. For more information on
hearing health and preservation, the ACEMg supplement, or to participate in the
OTIS study (limited initially to 200 adults aged 18 and older, residing in the
U.S.) please visit ClinicalTrials.gov. About Soundbites Soundbites is a Public
Benefit Corporation dedicated to hearing preservation for everyone, changing
the convention that hearing loss is inevitable with the world's first
clinically proven, affordable, preventive care biomedicine for hearing.
Grounded in decades of research from Dr. Josef Miller at the University of Michigan Medical
School, Soundbites offers the first scientifically backed antioxidant
supplement, ACEMg, for hearing preservation. Soundbites' mission is to make
lifelong hearing preservation accessible to everyone, reducing the personal,
social, and economic burdens of hearing loss. Business
inquiries: Barry
Seifer, barry@soundbites.com Media
Contact: Julie Fogerson, 425 503 3154
